JP2018519351A - オキシステロールおよびそれらの使用の方法 - Google Patents
オキシステロールおよびそれらの使用の方法 Download PDFInfo
- Publication number
- JP2018519351A JP2018519351A JP2018500417A JP2018500417A JP2018519351A JP 2018519351 A JP2018519351 A JP 2018519351A JP 2018500417 A JP2018500417 A JP 2018500417A JP 2018500417 A JP2018500417 A JP 2018500417A JP 2018519351 A JP2018519351 A JP 2018519351A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- alkyl
- pharmaceutically acceptable
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 C[C@](CCCC(*)(*)O)[C@@](CC1)[C@@](C)(CC2)[C@]1[C@](C)(CC1)[C@]2[C@@](C)(CC2)[C@]1C[C@@]2(*)O Chemical compound C[C@](CCCC(*)(*)O)[C@@](CC1)[C@@](C)(CC2)[C@]1[C@](C)(CC1)[C@]2[C@@](C)(CC2)[C@]1C[C@@]2(*)O 0.000 description 13
- AEHSZDXQXDLGCG-MZLNBKIZSA-N CC(C)C(C)(CCC[C@@H](C)C(CC1)[C@@](C)(CC[C@@]2([C@@](C)(CC[C@@](C)(C3)O)C3=CC3)I)[C@@H]1C23N)O Chemical compound CC(C)C(C)(CCC[C@@H](C)C(CC1)[C@@](C)(CC[C@@]2([C@@](C)(CC[C@@](C)(C3)O)C3=CC3)I)[C@@H]1C23N)O AEHSZDXQXDLGCG-MZLNBKIZSA-N 0.000 description 1
- LWTHEKRHBBWPMZ-HSCDOQPESA-N CC[C@H](CC[C@H](CCC[C@@H]1[C@@](C)(CC[C@@](C)(C2)O)C2=CC2)C12N)[C@H](C)CCCC(C)O Chemical compound CC[C@H](CC[C@H](CCC[C@@H]1[C@@](C)(CC[C@@](C)(C2)O)C2=CC2)C12N)[C@H](C)CCCC(C)O LWTHEKRHBBWPMZ-HSCDOQPESA-N 0.000 description 1
- BSWDPHACJZZFRD-SRBAREEQSA-N C[C@H](CCCC(C)(C)O)[C@@H](CC1)C(C)(CC2)[C@@H]1C1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCCC(C)(C)O)[C@@H](CC1)C(C)(CC2)[C@@H]1C1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 BSWDPHACJZZFRD-SRBAREEQSA-N 0.000 description 1
- QOAKPJIJMMVMPJ-RNPQCOGNSA-N C[C@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)C2[C@@](C)(CC2)C1C[C@@]2(C)O Chemical compound C[C@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)C2[C@@](C)(CC2)C1C[C@@]2(C)O QOAKPJIJMMVMPJ-RNPQCOGNSA-N 0.000 description 1
- QOAKPJIJMMVMPJ-JXNZKVSASA-N C[C@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O Chemical compound C[C@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O QOAKPJIJMMVMPJ-JXNZKVSASA-N 0.000 description 1
- FDMVAGWFPHCLNX-QHFORYHTSA-N C[C@H](CCCC(C)=O)[C@@H](CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@@](C)(C3)O)C3=CC3)[C@@H]1[C@@]23C=C Chemical compound C[C@H](CCCC(C)=O)[C@@H](CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@@](C)(C3)O)C3=CC3)[C@@H]1[C@@]23C=C FDMVAGWFPHCLNX-QHFORYHTSA-N 0.000 description 1
- GDPLZBJXJSPTAZ-LTITYAFTSA-N C[C@H](CCCCO)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCCCO)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 GDPLZBJXJSPTAZ-LTITYAFTSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189048P | 2015-07-06 | 2015-07-06 | |
| US62/189,048 | 2015-07-06 | ||
| US201662280394P | 2016-01-19 | 2016-01-19 | |
| US62/280,394 | 2016-01-19 | ||
| PCT/US2016/041168 WO2017007836A1 (en) | 2015-07-06 | 2016-07-06 | Oxysterols and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021002172A Division JP2021054864A (ja) | 2015-07-06 | 2021-01-08 | オキシステロールおよびそれらの使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018519351A true JP2018519351A (ja) | 2018-07-19 |
| JP2018519351A5 JP2018519351A5 (OSRAM) | 2019-07-25 |
Family
ID=57686105
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500417A Withdrawn JP2018519351A (ja) | 2015-07-06 | 2016-07-06 | オキシステロールおよびそれらの使用の方法 |
| JP2021002172A Withdrawn JP2021054864A (ja) | 2015-07-06 | 2021-01-08 | オキシステロールおよびそれらの使用の方法 |
| JP2022093073A Active JP7602513B2 (ja) | 2015-07-06 | 2022-06-08 | オキシステロールおよびそれらの使用の方法 |
| JP2024213240A Pending JP2025026573A (ja) | 2015-07-06 | 2024-12-06 | オキシステロールおよびそれらの使用の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021002172A Withdrawn JP2021054864A (ja) | 2015-07-06 | 2021-01-08 | オキシステロールおよびそれらの使用の方法 |
| JP2022093073A Active JP7602513B2 (ja) | 2015-07-06 | 2022-06-08 | オキシステロールおよびそれらの使用の方法 |
| JP2024213240A Pending JP2025026573A (ja) | 2015-07-06 | 2024-12-06 | オキシステロールおよびそれらの使用の方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10201550B2 (OSRAM) |
| EP (3) | EP3828194B1 (OSRAM) |
| JP (4) | JP2018519351A (OSRAM) |
| KR (2) | KR102703602B1 (OSRAM) |
| CN (2) | CN108135912B (OSRAM) |
| AU (3) | AU2016289967B2 (OSRAM) |
| BR (2) | BR112018000129B1 (OSRAM) |
| CA (1) | CA2991214C (OSRAM) |
| CO (1) | CO2018000660A2 (OSRAM) |
| CY (1) | CY1124496T1 (OSRAM) |
| DK (2) | DK3828194T3 (OSRAM) |
| ES (2) | ES2865258T3 (OSRAM) |
| FI (1) | FI3828194T3 (OSRAM) |
| HR (1) | HRP20210526T8 (OSRAM) |
| HU (1) | HUE053778T2 (OSRAM) |
| IL (2) | IL305404A (OSRAM) |
| LT (1) | LT3319611T (OSRAM) |
| MA (2) | MA55097A (OSRAM) |
| MD (1) | MD3319611T2 (OSRAM) |
| MX (2) | MX390302B (OSRAM) |
| PE (1) | PE20180483A1 (OSRAM) |
| PH (2) | PH12021551134A1 (OSRAM) |
| PL (2) | PL3319611T3 (OSRAM) |
| PT (2) | PT3319611T (OSRAM) |
| RS (1) | RS61718B1 (OSRAM) |
| RU (2) | RU2021100620A (OSRAM) |
| SG (1) | SG10202010553XA (OSRAM) |
| SI (1) | SI3319611T1 (OSRAM) |
| SM (1) | SMT202100226T1 (OSRAM) |
| WO (1) | WO2017007836A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| PL3436022T3 (pl) * | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| WO2018132676A1 (en) * | 2017-01-13 | 2018-07-19 | Duke University | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| JP2024520805A (ja) | 2021-06-11 | 2024-05-24 | セージ セラピューティクス， インコーポレイテッド | アルツハイマー病の治療のための神経活性ステロイド |
| CN113667734B (zh) * | 2021-07-16 | 2022-05-24 | 四川大学华西医院 | Shank3片段序列甲基化检测试剂在制备精神分裂症诊断试剂盒中的用途 |
| US20240368214A1 (en) * | 2021-08-25 | 2024-11-07 | Sage Therapeutics, Inc. | Positive nmda-modulating compounds and methods of use thereof |
| WO2023083979A1 (en) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2023143402A1 (zh) * | 2022-01-28 | 2023-08-03 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
| WO2024229297A1 (en) * | 2023-05-02 | 2024-11-07 | Sage Therapeutics, Inc. | Lymphatic system-targeting compounds |
| CN119371475B (zh) * | 2023-07-27 | 2025-11-04 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
| TW202508555A (zh) * | 2023-07-27 | 2025-03-01 | 大陸商珂闌(上海)醫藥科技有限公司 | 甾類化合物、其製備方法和應用 |
| WO2025020190A1 (zh) * | 2023-07-27 | 2025-01-30 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
| WO2025221732A1 (en) * | 2024-04-15 | 2025-10-23 | Sage Therapeutics, Inc. | Nmda receptor-modulating compounds and methods of use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160480A1 (en) * | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| WO2014160441A1 (en) * | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JP2014526469A (ja) * | 2011-09-08 | 2014-10-06 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| WO2016054551A1 (en) * | 2014-10-03 | 2016-04-07 | Progressive International Corporation | Salad spinner |
Family Cites Families (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (OSRAM) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| US4358406A (en) | 1981-07-27 | 1982-11-09 | Wisconsin Alumni Research Foundation | 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| ATE45347T1 (de) | 1985-05-30 | 1989-08-15 | Taisho Pharmaceutical Co Ltd | Vitamin d3-derivate. |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| AU609927B2 (en) | 1987-08-25 | 1991-05-09 | Kelvin W. Gee | Compositions and methods for alleviating stress, anxiety and seizure activity |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP0752860B1 (en) | 1994-02-14 | 2000-08-23 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| CA2205919A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| DE69634039T2 (de) | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| RU2182909C2 (ru) | 1995-06-23 | 2002-05-27 | Ново Нордиск А/С | Стероиды, способ регулирования мейоза |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997003677A1 (en) | 1995-07-24 | 1997-02-06 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| US5841272A (en) | 1995-12-20 | 1998-11-24 | Sundstrand Corporation | Frequency-insensitive current sensor |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) * | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| IL146230A0 (en) | 1999-04-29 | 2002-07-25 | Purdue Pharma Ltd | 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US6376530B1 (en) | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1392713B1 (en) | 2001-05-03 | 2007-10-17 | The University of Chicago | Liver x receptor agonists |
| CA2466033A1 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| PL213697B1 (pl) | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| GB0216621D0 (en) | 2002-07-17 | 2002-08-28 | Imaging Res Solutions Ltd | Imaging compounds |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004048364A1 (en) | 2002-11-22 | 2004-06-10 | Merck & Co., Inc. | 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| KR101358078B1 (ko) | 2004-11-01 | 2014-02-06 | 주식회사 유스팜인터내셔널 | 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물 |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| PL2711371T3 (pl) | 2006-11-21 | 2018-06-29 | Asarina Pharma Ab | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
| WO2008157786A1 (en) | 2007-06-20 | 2008-12-24 | Auspex Pharmaceutical, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| JP2011505357A (ja) | 2007-12-03 | 2011-02-24 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| EP2244577B1 (en) | 2008-01-25 | 2012-10-31 | Merck Sharp & Dohme Corp. | Quinolizidinone m1 receptor positive allosteric modulators |
| NZ589764A (en) | 2008-05-09 | 2012-10-26 | Univ Emory | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| GB201008047D0 (en) | 2010-05-14 | 2010-06-30 | Ge Healthcare Ltd | Method of synthesis |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| CA2874998A1 (en) | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| EP2736919A4 (en) | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| WO2013054822A1 (en) | 2011-10-07 | 2013-04-18 | Takeda Pharmaceutical Company Limited | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases |
| CN104136452A (zh) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| WO2014028942A2 (en) | 2012-08-17 | 2014-02-20 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
| JP2016505038A (ja) | 2013-01-23 | 2016-02-18 | スファエラ ファーマ プライベート リミテッド | ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物 |
| EA031905B1 (ru) | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| EP3049089B1 (en) | 2013-09-25 | 2019-08-21 | Van Andel Research Institute | Highly potent glucocorticoids |
| EP3102230B1 (en) | 2014-02-08 | 2021-04-28 | F. Hoffmann-La Roche AG | Methods of treating alzheimer's disease |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| CN107405352A (zh) | 2014-10-07 | 2017-11-28 | 萨奇治疗股份有限公司 | 神经活性化合物及其使用方法 |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
| CN110945006A (zh) | 2017-06-23 | 2020-03-31 | 英特塞普特医药品公司 | 用于制备胆汁酸衍生物的方法和中间体 |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
| BR112023023082A2 (pt) | 2021-05-04 | 2024-01-30 | Sage Therapeutics Inc | Esteroide neuroativo para o tratamento de comprometimento cognitivo suave associado a doença de parkinson |
| JP2024520805A (ja) | 2021-06-11 | 2024-05-24 | セージ セラピューティクス， インコーポレイテッド | アルツハイマー病の治療のための神経活性ステロイド |
-
2016
- 2016-07-06 SM SM20210226T patent/SMT202100226T1/it unknown
- 2016-07-06 RU RU2021100620A patent/RU2021100620A/ru unknown
- 2016-07-06 PE PE2018000034A patent/PE20180483A1/es unknown
- 2016-07-06 HR HRP20210526TT patent/HRP20210526T8/hr unknown
- 2016-07-06 FI FIEP21151891.5T patent/FI3828194T3/fi active
- 2016-07-06 AU AU2016289967A patent/AU2016289967B2/en active Active
- 2016-07-06 MX MX2020011449A patent/MX390302B/es unknown
- 2016-07-06 MA MA055097A patent/MA55097A/fr unknown
- 2016-07-06 RS RS20210461A patent/RS61718B1/sr unknown
- 2016-07-06 IL IL305404A patent/IL305404A/en unknown
- 2016-07-06 CN CN201680051035.5A patent/CN108135912B/zh active Active
- 2016-07-06 PL PL16821924T patent/PL3319611T3/pl unknown
- 2016-07-06 WO PCT/US2016/041168 patent/WO2017007836A1/en not_active Ceased
- 2016-07-06 US US15/742,425 patent/US10201550B2/en active Active
- 2016-07-06 MD MDE20180512T patent/MD3319611T2/ro unknown
- 2016-07-06 DK DK21151891.5T patent/DK3828194T3/da active
- 2016-07-06 EP EP21151891.5A patent/EP3828194B1/en active Active
- 2016-07-06 ES ES16821924T patent/ES2865258T3/es active Active
- 2016-07-06 PL PL21151891.5T patent/PL3828194T3/pl unknown
- 2016-07-06 SI SI201631146T patent/SI3319611T1/sl unknown
- 2016-07-06 EP EP16821924.4A patent/EP3319611B1/en active Active
- 2016-07-06 IL IL256710A patent/IL256710B2/en unknown
- 2016-07-06 PT PT168219244T patent/PT3319611T/pt unknown
- 2016-07-06 PH PH1/2021/551134A patent/PH12021551134A1/en unknown
- 2016-07-06 HU HUE16821924A patent/HUE053778T2/hu unknown
- 2016-07-06 CA CA2991214A patent/CA2991214C/en active Active
- 2016-07-06 BR BR112018000129-5A patent/BR112018000129B1/pt active IP Right Grant
- 2016-07-06 JP JP2018500417A patent/JP2018519351A/ja not_active Withdrawn
- 2016-07-06 CN CN202110670292.XA patent/CN113292623A/zh active Pending
- 2016-07-06 EP EP25170341.9A patent/EP4609866A3/en active Pending
- 2016-07-06 ES ES21151891T patent/ES3035617T3/es active Active
- 2016-07-06 DK DK16821924.4T patent/DK3319611T3/da active
- 2016-07-06 KR KR1020187003210A patent/KR102703602B1/ko active Active
- 2016-07-06 MA MA42410A patent/MA42410B1/fr unknown
- 2016-07-06 MX MX2018000282A patent/MX376833B/es active IP Right Grant
- 2016-07-06 RU RU2018104278A patent/RU2744267C2/ru active
- 2016-07-06 KR KR1020247029533A patent/KR20240137111A/ko active Pending
- 2016-07-06 SG SG10202010553XA patent/SG10202010553XA/en unknown
- 2016-07-06 PT PT211518915T patent/PT3828194T/pt unknown
- 2016-07-06 LT LTEP16821924.4T patent/LT3319611T/lt unknown
- 2016-07-06 BR BR122021005552-1A patent/BR122021005552B1/pt active IP Right Grant
- 2016-07-06 PH PH1/2018/500065A patent/PH12018500065B1/en unknown
-
2018
- 2018-01-24 CO CONC2018/0000660A patent/CO2018000660A2/es unknown
- 2018-12-20 US US16/227,099 patent/US10765685B2/en active Active
-
2020
- 2020-07-29 US US16/942,245 patent/US20210145848A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021002172A patent/JP2021054864A/ja not_active Withdrawn
- 2021-04-13 CY CY20211100316T patent/CY1124496T1/el unknown
- 2021-08-20 AU AU2021218228A patent/AU2021218228B2/en active Active
-
2022
- 2022-06-08 JP JP2022093073A patent/JP7602513B2/ja active Active
-
2024
- 2024-01-16 AU AU2024200268A patent/AU2024200268A1/en active Pending
- 2024-03-13 US US18/603,816 patent/US12268697B2/en active Active
- 2024-12-06 JP JP2024213240A patent/JP2025026573A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014526469A (ja) * | 2011-09-08 | 2014-10-06 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| WO2014160480A1 (en) * | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| WO2014160441A1 (en) * | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016054551A1 (en) * | 2014-10-03 | 2016-04-07 | Progressive International Corporation | Salad spinner |
Non-Patent Citations (1)
| Title |
|---|
| CNS NEUROSCIENCE & THERAPEUTICS, vol. ２１, JPN6020024299, 2015, pages 486 - 495, ISSN: 0004301597 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7602513B2 (ja) | オキシステロールおよびそれらの使用の方法 | |
| AU2022291419B2 (en) | Oxysterols and methods of use thereof | |
| AU2021218230B2 (en) | Oxysterols and methods of use thereof | |
| JP6882996B2 (ja) | オキシステロールおよびそれらの使用の方法 | |
| HK40053565A (en) | Oxysterols and methods of use thereof | |
| HK40053565B (en) | Oxysterols and methods of use thereof | |
| US20250387413A1 (en) | Oxysterols and methods of use thereof | |
| HK1247564B (en) | Oxysterols and methods of use thereof | |
| BR122023021450B1 (pt) | Compostos oxiesteróis, composição farmacêutica que os compreende e uso relacionado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200708 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210108 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210805 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210805 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20210816 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210903 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210906 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20211001 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20211005 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20211208 |